Background: In contrast to its well-known endocrine function, the role of inhibin in cancer development and therapeutic response is unclear. Salmonella, particularly less toxic attenuated Salmonella strains, are used to treat cancer in two ways. First, Salmonella accumulate around tumors, penetrate the cell barrier, and replicate inside the tumors. Second, Salmonella can act as a vehicle for delivering anticancer agents or proapoptotic genes to attack tumors. In this study, we aimed to develop a suitable cancer therapeutic strategy by genetically modifying attenuated Salmonella typhimurium to harbor short hairpin RNA (shRNA) expression plasmids targeting alpha subunit of inhibin (sh-INHA).
Introduction
Inhibin, a polypeptide hormone secreted by ovarian granulosa and testicular Sertoli cells in response to follicle-stimulating hormone (FSH), selectively downregulates FSH synthesis and secretion. Inhibin has also been considered a promising ovarian cancer marker. However, subsequent studies have shown that inhibin is not a very good marker in non-mucinous epithelial ovarian cancer cases.
Salmonella may be a useful cancer treatment tool due to their natural preference for infiltrating and replicating within the cells of cancer tumors [1] [2] [3] . Modified Salmonella typhimurium strains such as YS7212 [1] and VNP20009 [2, 3] target tumors and make the immune system aggressive toward cancer cells by penetrating the cell barriers of tumors and replicating inside them. In addition to this endogenous anticancer activity, Salmonella strains have also been utilized to deliver cancer therapeutic genes into target cancer cells or tissues [2, 4, 5] .
Here, we engineered attenuated S. typhimurium carrying a mammalian expression vector encoding short hairpin RNA (shRNA) targeting INHA (sh-INHA) as an efficient tumortargeting anticancer agent. Our results suggest that the combined tumoricidal effects of attenuated S. typhimurium and INHA knockdown have potential therapeutic advantages for the treatment of colon cancer and melanoma.
Materials and methods

Bacterial strains and growth conditions
For this study, we used the S. typhimurium BRD509 strain, which is an aroA aroD mutant of strain SL1344 [6, 7] . Expression vectors encoding sh-INHA and control scrambled shRNA (sh-Cont) were transfected into S. typhimurium SF586 [8] , followed by transformation into the BRD509 strain. The bacterial strains used in this study are described in supplementary Table S1 , available at Annals of Oncology online.
Generation of S. typhimurium expressing sh-INHA
To construct the plasmids expressing INHA shRNAs, we used a BLOCKiT Pol II miR RNAi expression vector system (Invitrogen). A pcDNA6.2-GW/EmGFP-miRNA vector containing a GFP-coding region within the precursor microRNA (pre-miRNA) expression cassette was inserted, with the following sequences: human INHA, 5 0 -TGCTGAGAAGGTT GGGCACTGTCTCATACTGTTTTGGCCACTGACTGACAGTATGAG ACAGTGCCCAACCTTCT-3 0 ; and mouse INHA, 5 0 -TGCTGTTGAG GTAGAGGCTACCACCTGTTTTGGCCACTGACTGACAGGTGGTAC TCTACCTCAA-3 0 . As a result, the pcDNA6.2-GW/EmGFP-miRNA vector contained the full INHA precursor shRNA (pre-shRNA) as well as the co-cistronic Emerald GFP (EmGFP) gene (supplementary Figure S3A , available at Annals of Oncology online). As a control shRNA-expressing plasmid, we used the pcDNA6.2-GW/EmGFP-miR-negative control plasmid (Invitrogen).
After sequence verification, the cassette carrying INHA EmGFP-preshRNA was transferred into intermediary S. typhimurium SF586 by electroporation, followed by transformation into S. typhimurium BRD590. Escherichia coli DH5a was used for DNA manipulation.
Cell culture
All normal and cancer cells used in this study are described in supplementary Table S2 , available at Annals of Oncology online.
Subcutaneous administration of S. typhimurium to mice
Mice were subcutaneously (s.c.) inoculated with 100 ll of 1Â 10 
Syngeneic mouse tumor model
Six-to seven-week-old female BALB/c and C57BL/6 mice were s.c. implanted on the mid-right side with CT26 (1 Â 10 6 ) colon cancer and B16F10 (1.5 Â 10 5 ) melanoma cells in 100 ll of PBS, respectively. When tumor volumes reached $50À70 mm 3 , the mice were randomly assigned into four groups: PBS, unmodified S. typhimurium, S. typhimurium/shCont, and S. typhimurium/sh-INHA. Tumor volumes were measured every 7 days and calculated as length Âwidth 2 Â0.52. Mice were deemed cured if they had no palpable tumors for at least 9 (for B16F10) or 12 (for CT26) weeks after treatment. The survival of each mouse was recorded, and overall survival was calculated.
For additional information, see supplementary methods, available at Annals of Oncology online.
Results
Enhanced expression of INHA in colon cancer/ melanoma
We examined INHA expression in human colon cancer and melanoma cells versus normal colon and melanocyte cells. Remarkably, higher INHA expression was detected in colon cancer and melanoma cell lines than in their normal counterparts ( Figure 1A ). Immunohistochemical staining showed that the proportions of samples with high INHA expression were significantly higher in tumor tissues than in normal adjacent tissues ( Figure 1B and Table 1 ).
INHA downregulation induced mild tumor cell cytotoxicity
We efficiently knocked down the expression of endogenous INHA using two different siRNAs in RKO and A375SM cells, whereas the scrambled negative control siRNA (si-Cont) had little effect on INHA expression (supplementary Figure S1 , available at Annals of Oncology online). Because INHA siRNA #2 (si-INHA #2) showed a higher efficacy in INHA knockdown (supplementary Figure S1 , available at Annals of Oncology online) and in cytotoxicity (data not shown) than INHA si-RNA #1 (si-INHA #1), we used siRNA #2 to delete INHA in subsequent experiments. We found that siRNA-mediated knockdown of INHA in RKO and A375SM cells mildly reduced cell viability ( Figure 2A ).
Next, the LDH level in the supernatants was higher in the si-INHA group than in the si-Cont and mock groups in both RKO and A375SM cells ( Figure 2B ). Mouse si-INHA also reduced cell viability and increased LDH levels in the supernatant in CT26 mouse colon cancer cells and B16F10 mouse melanoma cells (data not shown). These results indicate that INHA-knockdowninduced cytotoxic effects were associated with plasma membrane damage. 
INHA downregulation induced mild caspase activation
INHA downregulation reduced the levels of Bcl-2 and Bcl-xL
We found that the levels of Bcl-2 and Bcl-xL were moderately decreased in si-INHA-transfected RKO cells ( Figure 2D 
Engineered S. typhimurium induced cytotoxicity
Although the invasion rates of S. typhimurium/sh-Cont and S. typhimurium/sh-INHA were moderately lower than that of unmodified S. typhimurium ( Figure 3A ), S. typhimurium/sh-INHA exerted greater cytotoxic effects than unmodified S. typhimurium and S. typhimurium/sh-Cont ( Figure 3B) . Moreover, as shown in Figure 3C , LDH release from CT26 and B16F10 cells into the culture medium was significantly elevated after treatment with 
Engineered S. typhimurium induced apoptosis and downregulated anti-apoptotic Bcl-2 family proteins
Next, we determined whether the enhanced anticancer effects of S. typhimurium/sh-INHA were accompanied by enhanced apoptosis and reduced Bcl-2 family proteins. As shown in Figure 3D , unmodified S. typhimurium moderately increased the FLICA fluorescence intensity in CT26 cells, and the intensity was dramatically increased by S. typhimurium/sh-INHA. Furthermore, the S. typhimurium/sh-INHA-induced caspase activation was accompanied by reduced expression of Bcl-2 and Bcl-xL ( Figure  3E ). The same results for FLICA staining and Bcl-2 and Bcl-xL expression levels were obtained in B16F10 cells after treatment with The survival rates of all groups were recorded for up to 12 weeks (for CT26) or 9 weeks (for B16F10). Data are presented as Kaplan-Meier survival curves, and comparisons were made using the log-rank test (*P < 0.05 and **P < 0.01 versus PBS-treated control). samples). (B) Cell viability was assayed using trypan blue dye exclusion (*P < 0.05 and **P < 0.01 versus PBS-treated controls). (C) Cytotoxicity was determined by measuring the amount of LDH released from PBS-treated cells or S. typhimurium-treated cells into the supernatant with respect to cells exposed to a detergent (*P < 0.05 and **P < 0.01 versus PBS-treated controls). (D, E) CT26 cells were infected with the indicated S. typhimurium at an MOI of 500 for 60 h. (D) FLICA analysis was carried out with a fluorescence plate reader (*P < 0.05 and **P < 0.01 versus PBS-treated controls). (E) Western blotting was used to detect Bcl-2, Bcl-xL, and INHA.
S. typhimurium expressing mouse sh-INHA, and in RKO and A375SM cells after treatment with S. typhimurium expressing human sh-INHA (data not shown).
Engineered S. typhimurium inhibited tumor growth and prolonged survival in mouse models
To examine in vivo tumor response to engineered S. typhimurium, CT26 ( Figure 4A and B, left panel) and B16F10 ( Figure 4A and B, right panel) cells were grafted s.c. into BALB/c and C57BL/ 6 mice, respectively. Tumor growth was inhibited by unmodified S. typhimurium and by S. typhimurium/sh-Cont compared with PBS. However, treatment with S. typhimurium/sh-INHA resulted in more significant and prolonged tumor growth inhibition ( Figure 4A ). In mice treated with S. typhimurium/sh-INHA, about half of the mice with colon cancer or melanoma were cured of their tumors, with complete elimination of cancer cells and no recurrence.
Tumor-bearing mice treated with S. typhimurium/sh-INHA also survived for significantly longer periods than the tumorbearing mice in other groups ( Figure 4B ). We did not observe any signs of systemic toxicity or side-effects such as weight or hair loss in mice that received genetically modified S. typhimurium. Moreover, whereas unmodified S. typhimurium showed slight accumulation in the spleen, liver, and blood, but not in the lung or kidney, genetically modified S. typhimurium was not detected in any of the tissues evaluated (supplementary Figure S6A , available at Annals of Oncology online). Likewise, we found no histopathological signs of damage such as inflammation in any of the tissues evaluated after each treatment (supplementary Figure S6B , available at Annals of Oncology online). Therefore, the combined results of tumor growth and survival indicate that S. typhimurium/sh-INHA was effective in suppressing colon cancer and melanoma growth in immunocompetent mice.
Discussion
To overcome their own defects, such as limited spread in tumors and toxic effects to normal tissues, Salmonella strains with increased motility and attenuated toxicity have been developed. Moreover, genetically engineered Salmonella with the capacity to deliver antitumor agents and antitumor genes have been developed to target or destroy solid tumors. There have been three general cancer treatment approaches using Salmonella typhimurium: use of Salmonella itself on tumors; use of genetically engineered Salmonella to deliver anticancer agents such as immune cytokines and anticancer drugs on tumors; and use of genetically engineered Salmonella carrying a eukaryotic expression vector encoding anticancer genes, such as anti-angiogenic genes, tumor suppressors or proapoptotic genes, and RNAi.
Initially, INHA was known to be tumor-suppressive, and its expression is lower in human testicular and ovarian cancer than in normal counterparts, and lower in malignant forms of adrenal cancer versus benign forms. Downregulation or loss of INHA due to aberrant methylation-mediated transcriptional silencing of the INHA promoter has also been observed in prostate cancer, adrenocortical cancer, and gastric cancer. Most importantly, knockout studies in mice have shown that INHA is a tumor suppressor with gonadal and adrenal specificity [9, 10] . However, the role of INHA as a tumor suppressor has been challenged by several studies. For example, the majority of prostatectomy cases showed more intense INHA expression in cancer (especially high-grade prostate cancer) than in normal glands [11] . Moreover, it has been proposed that the tumor suppressing activities of INHA are dominant in nonmalignant tissue and then silenced as the tumor progresses, and that its oncogenic/prometastatic activities emerge during tumorigenesis and metastasis instead [12] .
Despite its purportedly different roles in different cancer types, the role of INHA in colon cancer and melanoma is unclear. Our immunoblotting and immunohistochemistry studies observed that INHA protein is highly expressed in colon cancer and melanoma cells and tissues compared with normal counterparts. A switch in gene function from tumor-suppressive to pro-oncogenic may account for the discrepant findings in other cancer types.
Apart from the purported opposing roles of INHA in earlyversus late-stage tumors (namely, INHA exerts tumor suppressor activity in the early stage of cancer and oncogenic activity in the late stage of cancer and metastasis), Salmonella seems to target the late stage of tumor progression for the following reasons. First, tumor-targeting S. typhimurium exhibits strong efficacy on treatment-resistant tumors such as disseminated and/or metastatic cancers. Second, tumor blood vessels increase with stage of tumor progression, and S. typhimurium can efficiently destroy tumor blood vessels. Third, advanced/late-stage cancer patients may be highly immune compromised; since tumor treatment with S. typhimurium can trigger an immune response, it might be possible to kill cancer cells in advanced/late-stage cancer patients by triggering an immune response. Therefore, considering the oncogenic activity of INHA and the therapeutic activity of S. typhimurium in late-stage cancers, our genetically engineered S. typhimurium/sh-INHA is expected to be effective against latestage cancers.
Our study was conducted to integrate Salmonella-based cancer therapy and gene-based cancer therapy, with an aim of synergistically improving treatment efficacy. Our research showed that S. typhimurium/sh-INHA exerted antitumor effects on colon cancer and melanoma in the cell culture model and in the syngeneic mouse model. We suggest that genetically engineering S. typhimurium harboring RNAi plasmid vectors may provide a promising new strategy for cancer therapy.
